Reimbursed Care Access in Botswana

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Psilocybin is a Schedule I/controlled psychotropic in the international conventions that Botswana implements into domestic controls; there is no published Botswana national programme or reimbursement pathway for medical psilocybin treatment. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. MDMA is controlled by the 1971 UN Convention and is treated as a prohibited/controlled psychotropic in most jurisdictions; there is no public evidence of MDMA being authorized, reimbursed, or available for clinical therapeutic programmes in Botswana. #.

Esketamine (Spravato) is an approved therapeutic for treatment‑resistant depression in certain jurisdictions but there is no public record in Botswana’s national essential medicines list or in Ministry of Health publications indicating a Botswana registration, national reimbursement programme, or routine clinical availability of esketamine. Botswana’s published Essential Medicines List (2016) explicitly lists ketamine injections under anaesthetics but does not list esketamine/Spravato, and no Botswana-specific registration listing for Spravato was found in the sources reviewed; therefore esketamine should be considered not registered and not reimbursed in routine public care absent a formal special‑access/registration notice. #.

Ketamine is an established anaesthetic and is explicitly listed on Botswana’s national Essential Medicines List (2016) for use as an anaesthetic preparation (ketamine 10 mg/mL and 50 mg/mL injections appear in the anaesthetics chapter). This indicates that ketamine is available within the public health system for accepted medical indications (primarily anaesthesia/emergency medicine) and is procured through Central Medical Stores and public hospital supply channels. Reimbursement: as an essential medicine supplied via the Ministry of Health public procurement / Central Medical Stores system, routine in‑public‑sector provision for approved indications is expected (subject to national procurement/stock levels and local facility formularies); private sector hospitals and clinics may also procure ketamine for surgical and emergency use. Off‑label psychiatric use (e.g., sub‑anaesthetic intravenous ketamine for depression) is an emergent global practice but is not described in Botswana policy documents as an approved, reimbursed psychiatric indication — any such use would generally be off‑label, clinician‑driven, and dependent on facility procurement and payer arrangements rather than an established national reimbursement pathway. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. DMT is listed under international psychotropic controls and consequently is controlled in most party states’ domestic law; there is no public evidence of Botswana permitting medical DMT access or reimbursement outside approved clinical trials. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. As a substituted tryptamine closely related to other internationally controlled tryptamines, 5‑MeO‑DMT is treated as a controlled psychotropic in jurisdictions implementing UN scheduling; no Botswana clinical access or reimbursement pathway was identified in the reviewed sources. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Ibogaine is not an accepted registered medicine in most jurisdictions and is typically unavailable for clinical prescription or reimbursement; no Botswana‑specific medical programme or reimbursement mechanism for ibogaine was identified. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. While ayahuasca as a botanical brew is sometimes treated differently culturally in some countries, its principal psychoactive constituent DMT is internationally controlled; Botswana has no public regulatory framework authorizing traditional ayahuasca use as reimbursed medical care. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline and mescaline‑containing extracts are controlled under international scheduling and Botswana has no published medical/reimbursement programme for mescaline therapy. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The 2C family and related substituted phenethylamines are typically captured by national psychotropic controls and/or analogue provisions; there is no evidence of therapeutic registration, clinical programmes, or reimbursement for 2C‑class compounds in Botswana. #.